Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines
Bernard R. Neustadt, Kwokei Ng, Jean E. Lachowicz, Geoffrey B. Varty(Institute of Neurobiology), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary Cohen-Williams, William J. Greenlee, Leyla Arik, Silva Fredduzzi(San Raffaele University of Rome), Hongtao Zhang(Chinese Academy of Sciences), Hong Liu(North West Agriculture and Forestry University), Jinsong Hao, Carolyn Foster, Rosalia Bertorelli(San Raffaele University of Rome)
Cited by 42
Related Papers
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416